Strides Arcolab, a pharmaceutical company manufacturing IP-led niche products, witnessed a rise in share price on Thursday after Stelis Biopharma, a wholly owned subsidiary of the company announced the ground-breaking for construction of its customized, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's premier park and ecosystem for industrial and healthcare biotechnology. Shares of the company are trading at Rs 983, up Rs 55, or 5.93%  at the Bombay Stock Exchange (BSE) on Thursday at 10:41 a.m. The scrip has touched an intra-day high of Rs 985.25 and low of Rs 923.70. The total volume of shares traded at the BSE is 175,042.